CMOR members Erta Kalanxi, Sebastian Meltzer and Anne Hansen Ree have published a new review article looking into the current state of knowledge around the heterogeneity and immunogenicity of colorectal cancer (CRC), with an emphasis on understanding the potential for combining conventional cytotoxic therapies (radiation, chemotherapy) with immune therapy. The paper takes in knowledge of the CRC tumour microenvironment and its heterogeneity at the molecular and cellular level, and how to use this information in CRC therapy studies of combined-modality cytotoxic agents and immune checkpoint inhibitors. The authors conclude the review with presenting the ongoing METIMMOX study that illustrates the various principles they have discussed.
You can read Erta, Sebastian and Anne’s paper here.
|Erta Kalanxi||Sebastian Meltzer||Anne Hansen Ree|